Evidence supporting the in vivo efficacy of targeting the AR NTD was shown by application of decoy AR1-558 molecules of AR NTD that inhibit the growth and hormonal progression of prostate cancer xenografts both in the presence and absence of androgen [2]. This evidence concerns the gene TCF20 and Familial prostate cancer.